A Stevenage-based neuroscience company has raised an oversubscribed £50m Series B funding round to advance its lead drug candidate.  NRG Therapeutics, which is targeting a novel mechanism to address mitochondrial dysfunction, saw the round led by SV Health Investors’ Dementia Discovery Fund (DDF). Other investors include British Business Bank, M Ventures, Novartis Venture Fund, Criteria … Continue reading NRG Therapeutics raises £50m to tackle neurodegenerative disorders